Bicalutamide Tablets

Developed to target prostate cancer activity, this medication is indicated to support the management of androgen-dependent disease progression in adult males.

Strengths: 50mg

Medicine details

Conditions
Alternative names

Casodex

Therapeutic class

Antiandrogen

Pharmacological class

Non-steroidal antiandrogen

Contraindications

hypersensitivity to bicalutamide; women; children

Minor side effects

hot flushes; fatigue; constipation

Moderate side effects

breast tenderness; gynaecomastia; nausea

Dosage forms

Film-coated tablet

Administration route

Oral use

Prescription status

POM

Manufacturer

AstraZeneca

Onset Time

1–2 weeks

Duration

long-term

Storage instructions

Store in the original container at room temperature.

Drug interactions

warfarin; ciclosporin

Age restrictions

Not for use in children or adolescents.

Pregnancy and breastfeeding

Not indicated for use in women.

Precautions and warnings

monitor liver function regularly; may cause dizziness; use with caution in hepatic impairment

Serious side effects

hepatic failure — requires immediate medical attention; interstitial lung disease — requires immediate medical attention

Patient summary

Developed to target prostate cancer activity, this medication is indicated to support the management of androgen-dependent disease progression in adult males.

Mechanism of action

Bicalutamide is a non-steroidal antiandrogen that inhibits the androgen receptor. By binding to these receptors, it prevents the action of androgens which stimulate the growth of prostate cancer cells, effectively mitigating tumour progression.

Bicalutamide Tablets

Developed to target prostate cancer activity, this medication is indicated to support the management of androgen-dependent disease progression in adult males.

Editorial Notes

  • Active ingredient(s): Bicalutamide
  • Listed indication(s): Prostate Cancer

Available option

  • 30 tablets - 50 mg1351-50-mg-16269